Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
INO
$1.09
+21.10%
INO · Inovio Pharmaceuticals, Inc.
$1.09
+0.19 (+21.10%)
At close · Aug 14
View the 10-K filed Mar 12, 2026
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Customer concentration
— top customer 100% of revenue
One customer — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Market Cap
$112.70M
Shares
103.40M
All earnings calls
Earnings call · FY2019 Q4
Inovio Pharmaceuticals, Inc. Q4 FY2019 Earnings Call
Inovio Pharmaceuticals, Inc. Q4 FY2019 Earnings Call
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Revenue
$279,488
-88.8% YoY
Diluted EPS
-$4.56
Net income
-$37.66M
Research materials
Open the source you need; every reader stays inside this workspace.
Quarter detail
How the reported period landed and where the business moved.
SEC filing · Item 2.02
8-K earnings release
Filed Mar 9, 2020 · complete as-filed document
SEC periodic report
10-K report
Filed Mar 12, 2020 · complete as-filed document